Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it presented additional results of its completed Phase 2 follow-on study of Flurizan™ in patients with mild Alzheimer's disease at the annual meeting of the American Association for Geriatric Psychiatry (AAGP), held March 1-4, 2007 in New Orleans.
Read the release in its entirety at The Alzheimer's Reading Room Weblog
Showing posts with label myriad. Show all posts
Showing posts with label myriad. Show all posts
Monday, March 5, 2007
Subscribe to:
Posts (Atom)